About PRASCEND® (pergolide mesylate)

PRASCEND is the first and only medicine available in the US that is fully approved by the FDA to treat pituitary pars intermedia dysfunction (more commonly called PPID or equine Cushing's disease) in horses.1,2 As part of the FDA approval process, PRASCEND was rigorously tested to prove its safety and effectiveness in reducing signs of PPID in horses.1,2

When you treat your horse with PRASCEND under guidance from your veterinarian, you can rest assured that you're giving your equine friend a medicine that is tested and trusted to work safely and consistently. These study results really mean that you can feel confident giving your horse PRASCEND to control signs of PPID! It may help get your horse back to his healthy, happy self again.

Read the full prescribing information

Important safety information

PRASCEND is for use in horses only. Treatment with PRASCEND may cause loss of appetite. Most cases are mild. Weight loss, lack of energy, and behavioral changes also may be observed. If severe, a temporary dose reduction may be necessary. PRASCEND has not been evaluated in breeding, pregnant, or lactating horses and may interfere with reproductive hormones in these horses. Using PRASCEND at the same time as drugs known as dopamine antagonists should be avoided. These drugs may diminish the effectiveness of PRASCEND. If your horse is especially sensitive to pergolide mesylate or similar products, PRASCEND should not be used. Refer to the package insert for complete product information.

References:

1. PRASCEND® (pergolide mesylate) [package insert]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011.

2. PRASCEND® (pergolide mesylate) [Freedom of Information Summary]. St Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011.